These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 18635234)
21. Obesity and urolithiasis: evidence of regional influences. Trinchieri A; Croppi E; Montanari E Urolithiasis; 2017 Jun; 45(3):271-278. PubMed ID: 27488444 [TBL] [Abstract][Full Text] [Related]
22. Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation. Koff SG; Paquette EL; Cullen J; Gancarczyk KK; Tucciarone PR; Schenkman NS Urology; 2007 Jun; 69(6):1013-6. PubMed ID: 17572176 [TBL] [Abstract][Full Text] [Related]
23. Urolithiasis: evaluation, dietary factors, and medical management: an update of the 2014 SIU-ICUD international consultation on stone disease. Jung H; Andonian S; Assimos D; Averch T; Geavlete P; Kohjimoto Y; Neisius A; Philip J; Saita A; Shah H; Osther PJ World J Urol; 2017 Sep; 35(9):1331-1340. PubMed ID: 28160089 [TBL] [Abstract][Full Text] [Related]
24. [Mineralogical composition of urinary stones, risk factors and metabolic disturbances in patients with calcium-oxalate urolithiasis]. Kustov AV; Strelnikov AI; Moryganov MA; Airapetyan AO; Smirnov PR; Lyalyakina EV; Toms SR Urologiia; 2017 Sep; (4):22-26. PubMed ID: 28952687 [TBL] [Abstract][Full Text] [Related]
25. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. Soygür T; Akbay A; Küpeli S J Endourol; 2002 Apr; 16(3):149-52. PubMed ID: 12028622 [TBL] [Abstract][Full Text] [Related]
26. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion. Domrongkitchaiporn S; Stitchantrakul W; Kochakarn W Am J Kidney Dis; 2006 Oct; 48(4):546-54. PubMed ID: 16997050 [TBL] [Abstract][Full Text] [Related]
27. Comparison of infants and children with urolithiasis: a large case series. Baştuğ F; Ağbaş A; Tülpar S; Yıldırım ZNY; Çiçek N; Günay N; Gemici A; Çelik B; Delebe EÖÇ; Nalçacıoğlu H; Yılmaz A; Gökçe İ; Demircin G; Hacıhamdioğlu DÖ; Yılmaz K; Atmış B; Yılmaz EK; Ertan P; Dursun İ; Aksu B; Akbulut BB; Döven SS; Öner N; Yel S; Elmacı AM; Atikel YÖ; Erfidan G; Uysal B; Bıyıklı N; Yazıcıoğlu B; Küçük N; Çomak E; Sever FL; Akil İ; Aksoy Ö; Alpay H Urolithiasis; 2022 Aug; 50(4):411-421. PubMed ID: 35482085 [TBL] [Abstract][Full Text] [Related]
28. Metabolic risk factors in pediatric and adult calcium oxalate urinary stone formers: is there any difference? Tefekli A; Esen T; Ziylan O; Erol B; Armagan A; Ander H; Akinci M Urol Int; 2003; 70(4):273-7. PubMed ID: 12740490 [TBL] [Abstract][Full Text] [Related]
29. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation. Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919 [TBL] [Abstract][Full Text] [Related]
30. Medical treatment of pediatric urolithiasis. Alon US Pediatr Nephrol; 2009 Nov; 24(11):2129-35. PubMed ID: 18273648 [TBL] [Abstract][Full Text] [Related]
31. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. Pak CY; Heller HJ; Pearle MS; Odvina CV; Poindexter JR; Peterson RD J Urol; 2003 Feb; 169(2):465-9. PubMed ID: 12544288 [TBL] [Abstract][Full Text] [Related]
32. Treatment Response in Patients with Stones, and Low Urinary pH and Hypocitraturia Stratified by Body Mass Index. Astroza GM; Neisius A; Tsivian M; Preminger GM; Lipkin ME J Urol; 2016 Mar; 195(3):653-7. PubMed ID: 26393903 [TBL] [Abstract][Full Text] [Related]
33. Metabolic disorders in Turkish children with urolithiasis. Celiksoy MH; Yilmaz A; Aydogan G; Kiyak A; Topal E; Sander S Urology; 2015 Apr; 85(4):909-13. PubMed ID: 25817115 [TBL] [Abstract][Full Text] [Related]
34. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Skolarikos A; Straub M; Knoll T; Sarica K; Seitz C; Petřík A; Türk C Eur Urol; 2015 Apr; 67(4):750-63. PubMed ID: 25454613 [TBL] [Abstract][Full Text] [Related]
35. Update on the evaluation of repeated stone formers. Kadlec AO; Turk TM Curr Urol Rep; 2013 Dec; 14(6):549-56. PubMed ID: 23749387 [TBL] [Abstract][Full Text] [Related]
36. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy. Pak CY; Sakhaee K; Fuller CJ Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957 [TBL] [Abstract][Full Text] [Related]
37. Pathophysiology and clinical aspects of urinary lithiasis. Vella M; Karydi M; Coraci G; Oriti R; Melloni D Urol Int; 2007; 79 Suppl 1():26-31. PubMed ID: 17726349 [TBL] [Abstract][Full Text] [Related]
38. Medical management of urinary stone disease. Pak CY Nephron Clin Pract; 2004; 98(2):c49-53. PubMed ID: 15499203 [TBL] [Abstract][Full Text] [Related]
39. Pediatric urolithiasis--evaluation of risk factors in 95 children. Erbagci A; Erbagci AB; Yilmaz M; Yagci F; Tarakcioglu M; Yurtseven C; Koyluoglu O; Sarica K Scand J Urol Nephrol; 2003; 37(2):129-33. PubMed ID: 12745721 [TBL] [Abstract][Full Text] [Related]
40. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Sterrett SP; Penniston KL; Wolf JS; Nakada SY Urology; 2008 Aug; 72(2):278-81. PubMed ID: 18533229 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]